BAMCO Inc
NBIX icon

BAMCO Inc’s Neurocrine Biosciences NBIX Stock Holding History

BAMCO Inc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-263,679
Closed -$25.4M – 385
2020
Q3 		$25.4M Buy
263,679
+106,199
+67% +$12.3M 0.08% 170
2020
Q2 		$19.2M Buy
157,480
+46,912
+42% +$5.18M 0.07% 174
2020
Q1 		$9.57M Buy
110,568
+78,965
+250% +$7.73M 0.05% 196
2019
Q4 		$3.4M Hold
31,603
– – 0.01% 274
2019
Q3 		$2.85M Buy
31,603
+200
+0.6% +$18.7K 0.01% 273
2019
Q2 		$2.65M Hold
31,403
– – 0.01% 288
2019
Q1 		$2.77M Hold
31,403
– – 0.01% 280
2018
Q4 		$2.24M Buy
31,403
+369
+1% +$35.4K 0.01% 284
2018
Q3 		$3.82M Buy
31,034
+1,334
+4% +$151K 0.02% 268
2018
Q2 		$2.92M Buy
+29,700
New +$2.66M 0.01% 266

Other funds holding NBIX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BAMCO Inc's NBIX Position: Q4 2020 in Review

BAMCO Inc sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 263,679 shares — an estimated $25.4M sold.

BAMCO Inc first reported a position in NBIX in Q2 2018 and held it in 10 quarters. The position peaked at $25.4M in Q3 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

  • BAMCO Inc reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
  • BAMCO Inc sold 263,679 Neurocrine Biosciences shares in Q4 2020, an estimated $25.4M.
  • BAMCO Inc first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 10 quarters.
  • BAMCO Inc's Neurocrine Biosciences position peaked at $25.4M in Q3 2020.
  • 406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on BAMCO Inc's 13F filing for Q4 2020, filed 12 Feb 2021.